{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLacebo&page=83",
    "query": {
      "intervention": "PLacebo",
      "page": 83
    },
    "page_size": 10
  },
  "pagination": {
    "page": 83,
    "page_size": 10,
    "total_count": 33211,
    "total_pages": 3322,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLacebo&page=84&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLacebo&page=82&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T13:13:07.173Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01572792",
      "title": "Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)",
          "type": "DRUG"
        },
        {
          "name": "Aclidinium bromide",
          "type": "DRUG"
        },
        {
          "name": "Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 921,
      "start_date": "2012-04",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-11-19T13:13:07.173Z",
      "location_count": 179,
      "location_summary": "Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 146 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01572792"
    },
    {
      "nct_id": "NCT02218736",
      "title": "Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)"
      ],
      "interventions": [
        {
          "name": "CERC-501",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 163,
      "start_date": "2015-06",
      "completion_date": "2017-12-01",
      "has_results": true,
      "last_update_posted_date": "2019-01-08",
      "last_synced_at": "2026-11-19T13:13:07.173Z",
      "location_count": 6,
      "location_summary": "New Haven, Connecticut • Indianapolis, Indiana • New York, New York + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02218736"
    },
    {
      "nct_id": "NCT04578834",
      "title": "Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LNP023",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 517,
      "start_date": "2021-01-25",
      "completion_date": "2025-09-19",
      "has_results": true,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-19T13:13:07.173Z",
      "location_count": 22,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Dimas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04578834"
    },
    {
      "nct_id": "NCT05149287",
      "title": "PROPER Trial of Pain and Inflammation After Knee Arthroscopy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Meniscus Tear",
        "Meniscus Lesion",
        "Cartilage Injury"
      ],
      "interventions": [
        {
          "name": "Ceftriaxone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Austin V Stone",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 5,
      "start_date": "2021-12-28",
      "completion_date": "2022-04-29",
      "has_results": true,
      "last_update_posted_date": "2023-09-05",
      "last_synced_at": "2026-11-19T13:13:07.173Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05149287"
    },
    {
      "nct_id": "NCT04922021",
      "title": "An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "LEO 138559",
          "type": "DRUG"
        },
        {
          "name": "LEO 138559 placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LEO Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 58,
      "start_date": "2021-07-14",
      "completion_date": "2022-09-26",
      "has_results": true,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-11-19T13:13:07.173Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04922021"
    },
    {
      "nct_id": "NCT06254612",
      "title": "A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "SP-624",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sirtsei Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 497,
      "start_date": "2024-03-25",
      "completion_date": "2026-07-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-11-19T13:13:07.173Z",
      "location_count": 50,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 46 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bryant",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Imperial",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06254612"
    },
    {
      "nct_id": "NCT01846481",
      "title": "A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid Dependence",
        "Opioid Related Disorders",
        "Cocaine Dependence"
      ],
      "interventions": [
        {
          "name": "RBP-8000 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cocaine",
          "type": "DRUG"
        },
        {
          "name": "RBP-8000 200 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indivior Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": "2013-04",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2016-09-23",
      "last_synced_at": "2026-11-19T13:13:07.173Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01846481"
    },
    {
      "nct_id": "NCT02312219",
      "title": "PET/CT Imaging Companion Study To ACTG A5314",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV",
        "Inflammation",
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Folic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Low Dose Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2014-11",
      "completion_date": "2016-12-08",
      "has_results": true,
      "last_update_posted_date": "2019-02-06",
      "last_synced_at": "2026-11-19T13:13:07.173Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02312219"
    },
    {
      "nct_id": "NCT06080165",
      "title": "Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "PTEN Gene Mutation",
        "PTEN Hamartoma Tumor Syndrome",
        "PTEN Hamartoma Syndrome"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "5 Years to 45 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-07",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-11-19T13:13:07.173Z",
      "location_count": 3,
      "location_summary": "Stanford, California • Boston, Massachusetts • Cleveland, Ohio",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06080165"
    },
    {
      "nct_id": "NCT05332067",
      "title": "Omalizumab Before Onset of Exacerbations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma in Children",
        "Atopy",
        "Viral Upper Respiratory Infection"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's National Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 300,
      "start_date": "2022-05-01",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-11-19T13:13:07.173Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05332067"
    }
  ]
}